Abstract
Adult acute lymphoblastic leukemia (ALL) has a poor overall survival compared with pediatric ALL where cure rates are observed in more than 90% of patients. The recent development of novel monoclonal antibodies targeting CD20, CD19, and CD22 has changed the long-term outcome of this disease, both in the frontline setting (e.g. rituximab) and for patients with relapsed/refractory disease (e.g. inotuzumab ozogamicin and blinatumomab). The CD3-CD19 bispecific T-cell-engaging antibody blinatumomab is also the first drug approved in ALL for patients with persistent or recurrent measurable residual disease, providing a new treatment paradigm for these patients. Several new agents are also in development that use novel constructs or target alternative surface epitopes such as CD123, CD25, and CD38. Herein, we review the role of monoclonal antibodies in adult ALL and summarize the current and future approaches in ALL, including novel combination therapies and the possibility of early incorporation of these agents into treatment regimens.
Original language | English (US) |
---|---|
Pages (from-to) | 1-17 |
Number of pages | 17 |
Journal | Therapeutic Advances in Hematology |
Volume | 10 |
DOIs | |
State | Published - 2019 |
Keywords
- acute lymphoblastic leukemia
- blinatumomab
- inotuzumab ozogamicin
- monoclonal antibodies
- rituximab
ASJC Scopus subject areas
- Hematology